The Experiences of Ethnic Minorities, and those with Liver Disease, during COVID-19, and The Impact on Related Health and Prevention Behaviors

少数民族和肝病患者在COVID-19期间的经历， 以及对相关健康和预防行为的影响 慢性B型肝炎（CH B）感染影响多达240万生活在美国的人，和 对亚洲和非洲裔以及太平洋岛民的影响尤为严重， 在医疗服务方面面临诸多挑战。代表的B型肝炎（PLHB）感染者 少数民族也缺乏获得临床试验的机会;推迟他们公平获得创新药物的机会。 药品，模糊了关于这种药物的安全性和有效性的真实情况， 这些社区使用的产品，并阻碍这些产品的可接受性和吸收， 少数民族的产品。最终，这会导致重大差距，甚至更糟 健康成果。PLHB和少数民族在临床试验中的代表性不足， SARS-CoV-2（COVID-19）疫苗。这导致规划地政及房屋局关注 疫苗会影响他们的肝脏或健康状况，并暴露了缺乏疫苗的现有差距。 药物开发商与代表PLHB和族裔的社区组织之间的对话 少数群体拟议的研究将有助于更好地了解挑战和由此产生的健康 少数群体个体的行为（包括COVID-19疫苗接种）， 包括PLHB，包括评估他们获得可信和以患者为中心的 有关COVID-19疫苗安全性的信息。该研究提出了一种混合方法 方法，收集和分析来自PLHB和少数民族及其医疗保健的数据 通过一对一的访谈和在线调查，该研究还提出， 成立一个知情的社区咨询委员会（CAB），由PLHB组成， 受CHB影响最大的种族人群。CAB成员将接受有关以下主题的培训： COVID-19、突发公共卫生事件和临床试验参与。CAB成员将培养 与药物开发界（如监管机构）进行可持续的对话 和药物开发商，特别是在公共卫生紧急情况下。本研究将 扩大我们对少数民族如何看待新批准的药物的理解 产品，以及改善未来有关这些产品的沟通的想法。研究结果 可用于促进COVID-19疫苗临床试验的多样性和包容性， 治疗和新开发的产品在其他疾病领域，并确保利益， 在美国和全球范围内，这些试验的一部分到达了最需要的社区。

The Experiences of Ethnic Minorities, and those with Liver Disease, during COVID-19, and The Impact on Related Health and Prevention Behaviors Chronic hepatitis B (CHB) infection affects up to 2.4 million people living in the U.S., and disproportionately impacts people of Asian and African origin and Pacific Islanders, who also face many challenges to healthcare access. People living with hepatitis B (PLHB) who represent ethnic minorities also lack access to clinical trials; delaying their equitable access to innovative medicinal products, blurring the true picture about the safety and effectiveness of such products when used by these communities, and hindering the acceptability and uptake of such products by members of ethnic minorities. Ultimately, this leads to major disparities and worse health outcomes. PLHB and ethnic minorities were underrepresented in clinical trials for the vaccine against SARS-CoV-2 (COVID-19). This has led PLHB to be concerned about how the vaccine would affect their liver or health condition and has exposed an existing gap of lack of dialogue between drug developers and community organizations representing PLHB and ethnic minorities. The proposed study will help better understand the challenges and resulting health behaviors (including COVID-19 vaccine uptake) among individuals from minority populations, including PLHB, including an assessment of their access to credible and patient-centered information on the safety of COVID-19 vaccines. The study proposes a mixed-methods approach, collecting and analyzing data from PLHB and ethnic minorities, and their healthcare providers, through one-on-one interviews and an online survey. The study also proposes establishing an informed community advisory board (CAB) composed of PLHB who represent ethnic populations most impacted by CHB. CAB members will be trained on topics related to COVID-19, public health emergencies, and clinical trial participation. CAB members will cultivate a sustainable dialogue with the drug development community, such as regulatory authorities and drug developers, especially during times of public health emergencies. This study will broaden our understanding of how ethnic minorities perceive newly approved medicinal products, and ideas for improving future communication about these products. Study results can be used to promote diversity and inclusion in clinical trials for COVID-19 vaccines and therapeutics and newly developed products in other disease areas, and ensure that the benefits of such trials reach the communities most in need, in the U.S. and globally.